Prix Algernon Health Inc. (AGNPF)

Algernon Health Inc is a CA-based company operating in industry. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2016-02-01. Algernon Health Inc., formerly Algernon Pharmaceuticals Inc., is a Canadian healthcare company. The firm is focused on the provision of brain-specific PET scanning services through a planned network of new clinics in North America for the early-stage detection of Alzheimer’s disease, as well as other forms of dementia, epilepsy, neuro-oncology, and movement disorders. The company is also the parent company of a private subsidiary called Algernon NeuroScience that has been advancing a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury recovery. The firm also owns a 20% equity position in Seyltx, a private U.S-based drug development company advancing a chronic cough drug called Ifenprodil.